Expression of miRNA in 5-FU resistant esophageal cancer

被引:9
|
作者
Mahawongkajit, Prasit [1 ]
Tomtitchong, Prakitpunthu [1 ]
机构
[1] Thammasat Univ, Fac Med, Dept Surg, Rangsit Campus,99-209 Moo 18,Paholyothin Rd, Amphur Klongluang 12120, Pathumthani, Thailand
关键词
microRNA; 5-FU resistant; esophageal squamous carcinoma cell; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR; NEOADJUVANT; MICRORNAS; SURVIVAL; SURGERY; ADENOCARCINOMA; POLYMORPHISM; OXALIPLATIN; CISPLATIN;
D O I
10.3892/mco.2020.2070
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fluoropyrimidine plus platinum (FP) are chemotherapeutic drugs that are most frequently used to treat esophageal squamous cell carcinoma (ESCC). However, drug resistance often occurs, and the mechanisms of resistance to 5-FU is yet to be determined. The role of micro (mi)RNAs has been well established in a variety of human cancers. The aim of the present study was to investigate the expression profile of ESCC, revealing the differential expression between ESCC and 5-FU resistant ESCC. The establishment of a 5-FU resistant (5-FUR) cell lines model provides a way of analyzing the expression of miRNAs in drug resistance. The miRNA expression indicated 50 miRNAs that were upregulated in TE10-5-FUR compared with TE10, while 119 miRNAs were downregulated. The TE11-5-FUR demonstrated 140 miRNAs were upregulated compared with TE11, which exhibited 12 downregulated miRNAs. Both cell lines share the 2 candidate upregulated miRNAs (miR-146a and miR-483-5p) and 5 downregulated miRNAs (miR-34a, miR-141, miR-200b, miR-200c and miR-205). Further studies are required to analyze and evaluate the function of the miRNAs.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 50 条
  • [1] Doxifluridine in patients with 5-FU resistant colorectal cancer
    Bajetta, E
    DiBartolomeo, M
    Somma, L
    Vicario, G
    Celio, L
    Bignami, P
    Bandieri, E
    Baldini, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 705 - 705
  • [2] Metabolome in 5-FU resistant gastric cancer organoids
    Sakamoto, Naoya
    Naka, Kazuhito
    Ukai, Shoichi
    Honma, Ririno
    Taniyama, Daiki
    Takashima, Tsuyoshi
    Maruyama, Ryota
    Tanabe, Kazuaki
    Ohdan, Hideki
    Yasui, Wataru
    CANCER RESEARCH, 2020, 80 (16)
  • [3] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [4] Combined administration of 5-FU with CDHP exert synergistic antitumor effect for 5-FU resistant gastric cancer cells
    Sasaki, E
    Tominaga, K
    Kuwamura, H
    Watanabe, T
    Fujiwara, Y
    Oshitani, N
    Higuchi, K
    Arakawa, T
    Proceedings of the 6th International Gastric Cancer Congress, 2005, : 229 - 231
  • [5] Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer.
    Yamanaka H.
    Motohiro T.
    Michiura T.
    Asai A.
    Mori T.
    Hioki K.
    The Japanese Journal of Thoracic and Cardiovascular Surgery, 1998, 46 (10): : 943 - 948
  • [6] Possibility of rescue for 5-FU-resistant gastric cancer by combination administration of 5-FU with CDHP
    Sasaki, E
    Tominaga, K
    Kuwamura, H
    Shiba, M
    Watanabe, T
    Fujiwara, Y
    Oshitani, N
    Higuchi, K
    Matsumoto, T
    Arakawa, T
    GASTROENTEROLOGY, 2003, 124 (04) : A555 - A555
  • [7] 5-FU for cervical cancer
    不详
    AIDS PATIENT CARE AND STDS, 2000, 14 (03) : 173 - 173
  • [8] 5-FU INDUCED ENCEPHALOPATHY DURING 5-FU CONTAINING REGIMEN FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA
    Kato, K.
    Hokamura, N.
    Akiyoshi, K.
    Honma, Y.
    Iwasa, S.
    Hamaguchi, T.
    Yamada, Y.
    Shimada, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 139 - 139
  • [9] Establishment and Analysis of 5-FU resistant organoids from gastric cancer
    Ukai, Shoichi
    Sakamoto, Naoya
    Honma, Ririno
    Fukada, Kaho
    Taniyama, Daiki
    Ishikawa, Akira
    Hattori, Takuya
    Sentani, Kazuhiro
    Oue, Naohide
    Yasui, Wataru
    CANCER SCIENCE, 2018, 109 : 1316 - 1316
  • [10] Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer
    Chester, JD
    Dent, JT
    Wilson, G
    Ride, E
    Seymour, MT
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 235 - 237